In a recent announcement, McDermott Will & Emery revealed that Michael Sitzman has joined the firm’s intellectual property practice as a partner in their San Francisco office. Sitzman is expected to play a significant role in augmenting McDermott’s robust capabilities within the biotechnology and pharmaceutical sectors, focusing on high-stakes biologic and drug patent litigation. This addition is seen as strategic for the firm’s growing influence in intellectual property law, particularly in these specialized areas.
Sitzman brings with him a wealth of experience in litigating complex cases involving cutting-edge technologies such as recombinant DNA, chimeric antigen receptor technology, glycobiology, and protein synthesis. His expertise also extends to small molecule drugs, antisense technology, and immunological markers, making him a highly valuable asset to McDermott’s lineup of IP professionals. More details about his hire were shared by McDermott here.
As the life sciences industry continues to evolve, the demand for proficient handling of patent disputes and IP litigation increases. Sitzman’s addition to McDermott aligns with this rising need, ensuring the firm remains at the forefront of delivering informed legal services to biotechnology and brand-side pharmaceutical clients.
The full press release and further insights into Sitzman’s appointment can be accessed via Bloomberg Law.